Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2021
Reporting Period: Three months ended September 30, 2021
Context: The filing announces the company's results of operations and financial condition for the third quarter of 2021 and provides a business update. The detailed financial data is contained in a press release dated November 15, 2021, which is incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The Form 8-K text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1). Consequently, the filing text does not provide a clear value for any specific financial figure.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It directs readers to the press release for the specific results of operations and financial condition for the three months ended September 30, 2021.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes forward-looking statements regarding future financial performance, which are subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent SEC filings for a comprehensive list of risks.
- Safe Harbor: Statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995.
- Unusual Items: No unusual items are described in the text of this specific 8-K form.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q3 2021 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Consult the most recent Form 10-K and subsequent filings for updated risk factors.
- Confirm the status of the company's clinical trials or business development activities mentioned in the business update.